Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BIOA with free AI briefings, catalyst countdowns, and dilution alerts.

BIOA · BioAge Labs, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$352.3M Cash on Hand
42.1mo Cash Runway
Follow BIOA by email Get an email when BIOA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BIOA, unsubscribe in one click. Privacy

📣 What BIOA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
BGE-117 Anemia Phase 2 · NCT04815603 Withdrawn
BGE-175 Covid19 Phase 2 · NCT04705597 Terminated
Azelaprag Obesity Phase 2 · NCT06515418 Terminated
Oral BGE-102 Obesity and Cardiovascular Risk Phase 2 · NCT07656727 Active not recruiting

Also used in these trials (approved or third-party drugs, not BIOA's own candidates): Bevacizumab, Tirzepatide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BIOA holds $352.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.1M/quarter from operations, an estimated runway of 42.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIOA files for a raise →

👥 Who Owns BIOA

Insiders 9.2% Institutions (215 holders) 90.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vijay Satyanand Pande
Director · +44,000 options
Insider 3,233,170 7.03% 2024-10-01
BlackRock, Inc. Institution (13G, 5%+) 2,236,460 4.87% 2026-03-31
Kristen Fortney
Chief Executive Officer, Director · +860,000 options
Insider 976,949 2.13% 2026-01-13
Dov A Md Goldstein
Chief Financial Officer · +358,420 options
Insider 36,575 0.08% 2026-04-23
Rekha Hemrajani
Director · +44,000 options
Insider 3,000 0.01% 2024-04-17

Share count 45,958,509 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BIOA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIOA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.